Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$3.21
-2.1%
$3.93
$2.42
$5.81
$84.26M1.1753,427 shs9,197 shs
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
$3.44
+0.6%
$4.00
$0.92
$16.95
$65.51M0.481.52 million shs652,486 shs
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$0.59
-3.3%
$0.61
$0.45
$3.47
$17.30M1.931.11 million shs130,137 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
-2.13%+2.23%-17.27%-27.70%-8.55%
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
+0.58%+2.69%-5.49%-5.75%+62.26%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
-3.04%-3.12%+2.63%-7.16%-77.94%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
2.1108 of 5 stars
3.55.00.00.00.00.80.0
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
0.8498 of 5 stars
0.04.00.03.91.40.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
3.00
Buy$10.00211.53% Upside
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$31.64M2.61$0.00 per share1,026.35$0.60 per share5.35
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/A$1.78 per shareN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$8.68M1.93N/AN/A$0.32 per share1.84

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
-$940K-$0.03N/AN/A-2.96%-6.21%-3.17%5/9/2024 (Estimated)
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
-$36.41MN/A0.00N/AN/A-91.03%-72.44%N/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
-$92.84M-$11.68N/AN/AN/A-1,069.29%-234.77%-47.11%5/20/2024 (Estimated)

Latest MLND, VBIV, and ETON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/14/2024Q4 2023
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
-$0.04-$0.09-$0.05-$0.09$7.70 million$7.31 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
N/AN/AN/AN/AN/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
N/A
1.65
1.60
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/A
6.39
6.39
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/A
0.48
0.37

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
27.86%
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
12.26%

Insider Ownership

CompanyInsider Ownership
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
13.16%
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
10.35%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
3025.69 million22.31 millionOptionable
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
1219.04 millionN/ANot Optionable
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
19028.43 million25.49 millionOptionable

MLND, VBIV, and ETON Headlines

SourceHeadline
VBI Vaccines (NASDAQ:VBIV) Now Covered by Analysts at StockNews.comVBI Vaccines (NASDAQ:VBIV) Now Covered by Analysts at StockNews.com
americanbankingnews.com - April 18 at 2:30 AM
VBI Vaccines Reports Full Year 2023 Financial ResultsVBI Vaccines Reports Full Year 2023 Financial Results
businesswire.com - April 16 at 8:00 AM
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesVBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
businesswire.com - April 11 at 4:05 PM
VBI Vaccines secures $2 million in direct offeringVBI Vaccines secures $2 million in direct offering
investing.com - April 11 at 3:23 PM
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesVBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
businesswire.com - April 9 at 2:45 PM
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent GlioblastomaVBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
businesswire.com - April 3 at 8:00 AM
VBI Vaccines expands collaboration with Canadian governmentVBI Vaccines expands collaboration with Canadian government
msn.com - April 2 at 5:12 PM
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine PlatformVBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
businesswire.com - April 2 at 8:00 AM
VBI Vaccines Inc. (VBIV)VBI Vaccines Inc. (VBIV)
finance.yahoo.com - March 31 at 8:25 AM
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial ResultsBrii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
finance.yahoo.com - March 22 at 7:40 AM
North Carolina biotech inks $30M deal to expand its global pipelineNorth Carolina biotech inks $30M deal to expand its global pipeline
bizjournals.com - February 15 at 3:37 PM
VBI signs deal to sell manufacturing capabilities, certain assets with Brii BiosciencesVBI signs deal to sell manufacturing capabilities, certain assets with Brii Biosciences
msn.com - February 14 at 6:34 PM
Brii Biosciences enters into multiple beneficial deals with VBI VaccinesBrii Biosciences enters into multiple beneficial deals with VBI Vaccines
thepharmaletter.com - February 14 at 1:33 PM
Strategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI VaccinesStrategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI Vaccines
finance.yahoo.com - February 14 at 1:33 PM
Why Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving PremarketWhy Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
benzinga.com - February 14 at 8:33 AM
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii BiosciencesVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
finance.yahoo.com - February 14 at 8:33 AM
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii BiosciencesVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
businesswire.com - February 14 at 7:00 AM
Brii Biosciences To Buy VBIs IP Rights In BRII-179Brii Biosciences To Buy VBI's IP Rights In BRII-179
markets.businessinsider.com - February 13 at 10:32 PM
Brii Biosciences Announces Agreement to Acquire VBIs IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial SuppliesBrii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
prnewswire.com - February 13 at 7:04 PM
VBI Vaccines Secures Forbearance Agreement ExtensionsVBI Vaccines Secures Forbearance Agreement Extensions
msn.com - February 7 at 9:52 AM
VBI Vaccines Inc. [VBIV] Investment Guide: What You Need to KnowVBI Vaccines Inc. [VBIV] Investment Guide: What You Need to Know
knoxdaily.com - January 2 at 4:56 AM
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual MeetingVBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
finance.yahoo.com - November 20 at 10:15 AM
VBI Vaccines Non-GAAP EPS of -$0.38, revenue of $6.62M misses by $6.63MVBI Vaccines Non-GAAP EPS of -$0.38, revenue of $6.62M misses by $6.63M
msn.com - November 14 at 6:09 PM
VBI Vaccines Reports Third Quarter 2023 Financial ResultsVBI Vaccines Reports Third Quarter 2023 Financial Results
finance.yahoo.com - November 14 at 6:09 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Eton Pharmaceuticals logo

Eton Pharmaceuticals

NASDAQ:ETON
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Millendo Therapeutics logo

Millendo Therapeutics

NASDAQ:MLND
As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.
VBI Vaccines logo

VBI Vaccines

NASDAQ:VBIV
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.